We have been in discussion with MSF. MSF have come to Apotex and asked us to produce a quantity of this triple combination therapy, which we have produced. We can supply it. The price at which we're prepared to supply it is competitive with products that would come out of India. The only reason we have not supplied it to MSF, who have assured us they will get the products to the patients who need it to save lives, is we cannot stickhandle our way through the current legislation.
On April 23rd, 2007. See this statement in context.